FRANKLIN, Ohio & BRONX, N.Y., June 2026
NanoDetection Technology (NDT) and Oligomerix announced an exclusive worldwide licensing agreement granting NanoDetection rights to develop and commercialize diagnostic tests based on a proprietary panel of nine Tau antibodies discovered by Oligomerix. The agreement provides NanoDetection with exclusive global diagnostic rights to the antibody portfolio, while Oligomerix retains rights for therapeutic applications. The antibodies are designed to identify distinct Tau protein species associated with neurodegenerative diseases, supporting the development of next-generation diagnostic technologies.
Antibody Platform Enables Detailed Characterization of Disease-Associated Tau
The licensed antibody panel is designed to differentiate among multiple forms of Tau protein, including cleavage-specific and conformationally altered species found within pathological protein aggregates. This capability may help distinguish Alzheimer’s disease from other Tau-related neurodegenerative disorders such as Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD). The technology also provides a framework for quantitative analysis of disease-associated protein aggregation, a key hallmark of neurodegenerative disease progression.
TRACE-Tau™ Platform Advances Quantitative Biomarker Development
NanoDetection has incorporated the antibody portfolio into its proprietary TRACE-Tau™ platform to support quantitative monitoring of protein-state transitions throughout the Alzheimer’s disease continuum. The assays are being developed for use on the company’s Luminorix™ diagnostic instrument utilizing its Accuglo™ chemiluminescent assay technology. Unlike conventional assays that primarily measure total Tau or phosphorylated Tau, the TRACE-Tau platform is designed to specifically detect aggregated Tau species believed to be more directly associated with active disease pathology.
Advertisement
Human Sample Studies Support Ongoing Clinical Validation Efforts
Analyses conducted using samples from patients with Alzheimer’s disease have demonstrated the ability to detect and characterize aggregated Tau species across multiple human sample types. NanoDetection is continuing validation efforts in cerebrospinal fluid through collaborations with research teams at UMass Chan Medical School, aiming to further establish the translational and clinical utility of the platform. The companies believe the technology could provide important new tools for improving diagnosis, disease characterization, and monitoring of neurodegenerative disorders.
Source: NanoDetection Technology press release
